Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase‐positive non‐small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report
Author:
Affiliation:
1. Department of Medical Oncology Hirosaki University Graduate School of Medicine Aomori Japan
2. Department of Internal medicine Aomori Kyoritsu Hospital Aomori Japan
3. Department of Pharmacy Aomori Kyoritsu Hospital Aomori Japan
Publisher
Wiley
Subject
Pulmonary and Respiratory Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/rcr2.796
Reference6 articles.
1. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
2. Enteral tube administration of oral chemotherapy drugs
3. Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
4. Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
5. Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. “Transcriptomic Profiling Unveils Novel Therapeutic Options for Drug-Resistant Temporal Lobe Epilepsy”;2024-06-26
2. Alternatives for the administration of oral antineoplastics in patients with swallowing difficulties;Journal of Chemotherapy;2024-05-20
3. Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report;Oncology Letters;2023-10-23
4. Lorlatinib as a treatment for ALK-positive lung cancer;Future Oncology;2022-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3